Table 1.
Selected oncology targeted and immunotherapy approvals since 2013 (adapted from Blumenthal et al 3)
| Indication | Therapy (target) |
|---|---|
| Anaplastic LCL | Brentuximab vedotin (CD30) |
| ALL (Philadelphia negative) | Blinatumomab (CD19/CD3) |
| B‐cell NHL | Idelalisib (PI3K delta) |
| Basal cell | Sonidegib (hedgehog pathway) |
| Breast cancer | Palbociclib (CDK 4 and 6); pertuzumab (HER2/neu) |
| CLL | Ibrutinib (BTK); idelalisib (PI3K delta); obinutuzumab, ofatumumab (CD20); venetoclax (BCL‐2/17p deletion) |
| Follicular lymphoma | Obinutuzumab (CD20) |
| HNSCC | Nivolumab, pembrolizumab (PD‐1) |
| Hodgkin's lymphoma | Brentuximab vedotin (CD30); nivolumab (PD‐1) |
| Mantle cell lymphoma, WM | Ibrutinib (BTK) |
| Metastatic melanoma | Cobimetinib, trametinib (BRAF/MEK); vemurafenib, dabrafenib (BRAF/MEK); Ipilimumab (CTLA4); nivolumab, pembrolizumab (PD‐1) |
| Metastatic NSCLC | Afatinib, erlotinib, gefitinib, osimertinib (EGFR); alectinib, ceritinib, crizotinib (ALK); crizotinib (ROS‐1); atezolizumab, pembrolizumab, nivolumab (PD‐1/PD‐L1) |
| Multiple myeloma | Carfilzomib, Ixazomib (proteasome); elotuzumab (SLAMF7) |
| Ovarian | Olaparib, rucaparib (PARP/ BRCA) |
| Renal cell carcinoma | Nivolumab (PD‐1) |
| Soft tissue sarcoma | Olaratumab (PDGFR‐alpha) |
| Urothelial | Atezolizumab (PD‐L1) |
Anaplastic LCL, Anaplastic large cell lymphoma; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; HNSCC, head and neck squamous cell carcinoma; metastatic NSCLC, metastatic non‐small cell lung cancer; WM, Waldenström's macroglobulinemia. Ref: http://www.accessdata.fda.gov/scripts/cder/daf/